All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.

The ALL Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
  TRANSLATE

The ALL Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the ALL Hub cannot guarantee the accuracy of translated content. The ALL Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
Visit:
AML HubGVhD HubLymphoma HubMDS HubMPN HubMultiple Myeloma Hub

Blinatumomab injection approved in China for pediatric relapsed or refractory CD19+ B-cell precursor acute lymphoblastic leukemia

May 7, 2022
Share:
Learning objective: After reading this article, learners will be able to cite a new clinical development in ALL

On May 4, 2022, it was announced that blinatumomab for injection received conditional approval from the China National Medical Products Administration (NMPA) for the treatment of pediatric patients with relapsed or refractory (R/R) CD19+ B-cell precursor acute lymphoblastic leukemia (B-ALL).

Blinatumomab is an anti-CD19 bispecific T-cell engager; other indications and prior approvals are outlined below.

NMPA

In December 2020, blinatumomab received conditional approval from the NMPA for the treatment of R/R CD19+ B-ALL in adult patients, a decision based on an interim analysis of a phase III, multicenter clinical trial (NCT03476239).

U.S. Food and Drug Administration

In March 2018, following breakthrough therapy and priority review designations, blinatumomab was approved by the U.S. Food and Drug Administration (FDA) to treat adults and children with

  • R/R CD19+ B-ALL
  • CD19+ B-ALL in first or second complete remission with minimal residual disease ≥0.1%

European Union

In January 2019, Blinatumomab was approved in the European Union (EU) as a monotherapy to treat

  • Adults with Ph CD19+ R/R B-ALL who failed treatment with ≥2 tyrosine kinase inhibitors and have no alternate option.
  • Adults with Ph CD19+ B-ALL in first or second complete remission with minimal residual disease ≥0.1%.
  • Pediatric patients ≥1 year of age with Ph CD19+ R/R B-ALL who had received ≥2 prior therapies or are in relapse after receiving prior allogeneic hematopoietic stem cell transplantation.
  • Pediatric patients ≥1 year of age with high-risk first relapsed Ph CD19+ R/R B-ALL as part of consolidation therapy.

  1. BeiGene Announces the Approval in China of BLINCYTO® (Blinatumomab) for Injection for Pediatric Patients with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (ALL). https://www.businesswire.com/news/home/20220504005602/en/BeiGene-Announces-the-Approval-in-China-of-BLINCYTO%C2%AE-Blinatumomab-for-Injection-for-Pediatric-Patients-with-Relapsed-or-Refractory-B-Cell-Precursor-Acute-Lymphoblastic-Leukemia-ALL. Published May 5, 2022. Accessed May 5, 2022.

Share: